BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Nachury M, Moreau J. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380:1909-1915. [PMID: 23063316 DOI: 10.1016/s0140-6736(12)61084-8] [Cited by in Crossref: 342] [Cited by in F6Publishing: 124] [Article Influence: 34.2] [Reference Citation Analysis]
Number Citing Articles
1 Brand S. Für jedes Stadium und Befallsmuster die passende Therapie wählen. MMW - Fortschritte der Medizin 2015;157:45-50. [DOI: 10.1007/s15006-015-2648-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Grinspan A, Kornbluth A. Positioning Therapy for Ulcerative Colitis. Curr Gastroenterol Rep 2015;17:29. [PMID: 26143627 DOI: 10.1007/s11894-015-0454-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
3 McClements D, Probert C. Managing acute severe ulcerative colitis in the hosptialised setting. Frontline Gastroenterol 2015;6:241-5. [PMID: 28839817 DOI: 10.1136/flgastro-2014-100459] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
4 Ng SC, Mak JWY, Pal P, Banerjee R. Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia. Lancet Gastroenterol Hepatol 2020;5:1089-100. [PMID: 33181088 DOI: 10.1016/S2468-1253(20)30298-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Al-Ani AH, Prentice RE, Christensen B. Letter to the Editor: Care of the Patient with IBD Requiring Hospitalisation During the COVID-19 Pandemic. J Crohns Colitis 2020:jjaa183. [PMID: 32929469 DOI: 10.1093/ecco-jcc/jjaa183] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Zhao J, Zhang B, Mao Q, Ping K, Zhang P, Lin F, Liu D, Feng Y, Sun M, Zhang Y, Li QH, Zhang T, Mou Y, Wang S. Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5-ASA-PABA-MAC and 5-ASA-PABA-Diamine for the Treatment of Ulcerative Colitis. J Med Chem 2022. [PMID: 35275619 DOI: 10.1021/acs.jmedchem.1c02166] [Reference Citation Analysis]
7 Kaur M, Targan SR. Ulcerative colitis: steroid-refractory ulcerative colitis-ciclosporin or infliximab? Nat Rev Gastroenterol Hepatol 2013;10:8-9. [PMID: 23229328 DOI: 10.1038/nrgastro.2012.235] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
8 Cushing KC, Kordbacheh H, Gee MS, Kambadakone A, Ananthakrishnan AN. CT-Visualized Colonic Mural Stratification Independently Predicts the Need for Medical or Surgical Rescue Therapy in Hospitalized Ulcerative Colitis Patients. Dig Dis Sci 2019;64:2265-72. [PMID: 30796684 DOI: 10.1007/s10620-019-05520-x] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Bonovas S, Pansieri C, Piovani D, Macaluso FS, Orlando A, Festa S, Papi C, Pugliese D, Armuzzi A. Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD technical review based on the GRADE methodology. Dig Liver Dis 2022:S1590-8658(22)00134-7. [PMID: 35183439 DOI: 10.1016/j.dld.2022.01.123] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Pedersen J, Coskun M, Soendergaard C, Salem M, Nielsen OH. Inflammatory pathways of importance for management of inflammatory bowel disease. World J Gastroenterol 2014; 20(1): 64-77 [PMID: 24415859 DOI: 10.3748/wjg.v20.i1.64] [Cited by in CrossRef: 90] [Cited by in F6Publishing: 84] [Article Influence: 11.3] [Reference Citation Analysis]
11 Chiba M, Tsuji T, Nakane K, Tsuda S, Ishii H, Ohno H, Obara Y, Komatsu M, Tozawa H. High Remission Rate with Infliximab and Plant-Based Diet as First-Line (IPF) Therapy for Severe Ulcerative Colitis: Single-Group Trial. Perm J 2020;24:1-10. [PMID: 33482946 DOI: 10.7812/TPP/19.166] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Vanga R, Long MD. Contemporary Management of Ulcerative Colitis. Curr Gastroenterol Rep. 2018;20:12. [PMID: 29589185 DOI: 10.1007/s11894-018-0622-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
13 Viscido A, Papi C, Latella G, Frieri G. Has infliximab influenced the course and prognosis of acute severe ulcerative colitis? Biologics 2019;13:23-31. [PMID: 31114154 DOI: 10.2147/BTT.S179006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
14 Atreya R, Neurath MF. IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality. J Crohns Colitis 2022;16:ii54-63. [PMID: 35553662 DOI: 10.1093/ecco-jcc/jjac007] [Reference Citation Analysis]
15 Wendt E, Keshav S. CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease. Clin Exp Gastroenterol 2015;8:119-30. [PMID: 25897254 DOI: 10.2147/CEG.S48305] [Cited by in Crossref: 7] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
16 Pouillon L, Travis S, Bossuyt P, Danese S, Peyrin-Biroulet L. Head-to-head trials in inflammatory bowel disease: past, present and future. Nat Rev Gastroenterol Hepatol 2020;17:365-76. [PMID: 32303700 DOI: 10.1038/s41575-020-0293-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
17 De Simone B, Davies J, Chouillard E, Di Saverio S, Hoentjen F, Tarasconi A, Sartelli M, Biffl WL, Ansaloni L, Coccolini F, Chiarugi M, De'Angelis N, Moore EE, Kluger Y, Abu-Zidan F, Sakakushev B, Coimbra R, Celentano V, Wani I, Pintar T, Sganga G, Di Carlo I, Tartaglia D, Pikoulis M, Cardi M, De Moya MA, Leppaniemi A, Kirkpatrick A, Agnoletti V, Poggioli G, Carcoforo P, Baiocchi GL, Catena F. WSES-AAST guidelines: management of inflammatory bowel disease in the emergency setting. World J Emerg Surg 2021;16:23. [PMID: 33971899 DOI: 10.1186/s13017-021-00362-3] [Reference Citation Analysis]
18 Vermeire S, Rutgeerts P. IBD in 2012: Pathogenesis and management of IBD--thinking outside the box. Nat Rev Gastroenterol Hepatol 2013;10:67-9. [PMID: 23296248 DOI: 10.1038/nrgastro.2012.241] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
19 Moore H, Dolce P, Devas N, Baldassano R, Martinelli M. Post-induction infliximab trough levels and disease activity in the clinical evolution of pediatric ulcerative colitis. United European Gastroenterol J 2020;8:425-35. [PMID: 32213038 DOI: 10.1177/2050640620912877] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Xiao Y, Benoit N, Sedano R, Jairath V, Narula N, McCurdy JD, Rosenfeld G, Afif W, Lakatos PL, Bessissow T. Effectiveness of Tofacitinib for Hospitalized Patients with Acute Severe Ulcerative Colitis: Case Series. Dig Dis Sci 2022. [PMID: 35244825 DOI: 10.1007/s10620-022-07439-2] [Reference Citation Analysis]
21 Fausel R, Afzali A. Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists. Ther Clin Risk Manag 2015;11:63-73. [PMID: 25609972 DOI: 10.2147/TCRM.S55506] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
22 Fleshner P, Melmed GY. Acute Severe Colitis: The Need for Joint Management between Gastroenterologists and Surgeons. Clin Colon Rectal Surg 2022;35:066-71. [DOI: 10.1055/s-0041-1740030] [Reference Citation Analysis]
23 Nalagatla N, Falloon K, Tran G, Borren NZ, Avalos D, Luther J, Colizzo F, Garber J, Khalili H, Melia J, Bohm M, Ananthakrishnan AN. Effect of Accelerated Infliximab Induction on Short- and Long-term Outcomes of Acute Severe Ulcerative Colitis: A Retrospective Multicenter Study and Meta-analysis. Clin Gastroenterol Hepatol 2019;17:502-509.e1. [PMID: 29944926 DOI: 10.1016/j.cgh.2018.06.031] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 7.8] [Reference Citation Analysis]
24 Ogino T, Mizushima T, Matsuda C, Mori M, Doki Y. Essential updates 2018/2019: Colorectal (benign): Recent updates (2018-2019) in the surgical treatment of benign colorectal diseases. Ann Gastroenterol Surg 2020;4:30-8. [PMID: 32021956 DOI: 10.1002/ags3.12304] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
25 Hsieh AH, Ferman M, Brown MP, Andrews JM. Vedolizumab: a novel treatment for ipilimumab-induced colitis. BMJ Case Rep. 2016;2016. [PMID: 27539137 DOI: 10.1136/bcr-2016-216641] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
26 Patel P, Yarur A, Dalal S, Sakuraba A, Rubin DT, Hanauer SB, Hanan I, Raffals LH, Cohen RD, Pekow J. Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. Inflamm Bowel Dis 2018;24:1291-7. [PMID: 29506124 DOI: 10.1093/ibd/izx105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
27 Melsheimer R, Geldhof A, Apaolaza I, Schaible T. Remicade® (infliximab): 20 years of contributions to science and medicine. Biologics 2019;13:139-78. [PMID: 31440029 DOI: 10.2147/BTT.S207246] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
28 Dulai PS, Jairath V. A Microsimulation Model to Project the 5-Year Impact of Using Hyperbaric Oxygen Therapy for Ulcerative Colitis Patients Hospitalized for Acute Flares. Dig Dis Sci 2021;66:3740-52. [PMID: 33185788 DOI: 10.1007/s10620-020-06707-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Seo SH, Unno T, Park SE, Kim EJ, Lee YM, Na CS, Son HS. Korean Traditional Medicine (Jakyakgamcho-tang) Ameliorates Colitis by Regulating Gut Microbiota. Metabolites 2019;9:E226. [PMID: 31615012 DOI: 10.3390/metabo9100226] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
30 Tan CX, Brand HS, de Boer NK, Forouzanfar T. Gastrointestinal diseases and their oro-dental manifestations: Part 2: Ulcerative colitis. Br Dent J. 2017;222:53-57. [PMID: 28084352 DOI: 10.1038/sj.bdj.2017.37] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
31 Törüner M, Akpınar H, Akyüz F, Dağlı Ü, Över Hamzaoğlu H, Tezel A, Ünsal B, Yıldırım S, Çelik AF. 2019 Expert opinion on biological treatment use in inflammatory bowel disease management. Turk J Gastroenterol 2019;30:S913-46. [PMID: 32207688 DOI: 10.5152/tjg.2019.061119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Whaley KG, Rosen MJ. Contemporary Medical Management of Acute Severe Ulcerative Colitis. Inflamm Bowel Dis 2019;25:56-66. [PMID: 29889235 DOI: 10.1093/ibd/izy208] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
33 Vasudevan A, Gibson PR, Langenberg DRV. Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told? World J Gastroenterol 2017; 23(35): 6385-6402 [PMID: 29085188 DOI: 10.3748/wjg.v23.i35.6385] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
34 Uzzan M, Colombel JF, Cerutti A, Treton X, Mehandru S. B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases. Dig Dis Sci 2016;61:3407-24. [PMID: 27655102 DOI: 10.1007/s10620-016-4317-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
35 Kim EH, Kim DH, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study. Gut Liver 2015;9:601-6. [PMID: 25473080 DOI: 10.5009/gnl14120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
36 Siegmund B. Janus Kinase inhibitors in the New Treatment Paradigms of Inflammatory Bowel Disease. J Crohns Colitis 2020;14:S761-6. [PMID: 31922534 DOI: 10.1093/ecco-jcc/jjaa003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
37 Feuerstein JD, Akbari M, Tapper EB, Cheifetz AS. Systematic review and meta-analysis of third-line salvage therapy with infliximab or cyclosporine in severe ulcerative colitis. Ann Gastroenterol 2016;29:341-7. [PMID: 27366036 DOI: 10.20524/aog.2016.0032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
38 Bernstein CN, Kornbluth A. Yes, We Are Still Talking about Cylosporin vs. Infliximab in Steroid Resistant Acute Severe Ulcerative Colitis. Am J Gastroenterol 2017;112:1719-21. [PMID: 29109492 DOI: 10.1038/ajg.2017.282] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
39 Saito D, Matsuura M, Ozaki R, Tokunaga S, Minowa S, Mitsui T, Miura M, Sakuraba A, Hayashida M, Miyoshi J, Hisamatsu T. Clinical response of vedolizumab at week 6 predicted endoscopic remission at week 24 in ulcerative colitis. JGH Open 2021;5:1056-62. [PMID: 34584975 DOI: 10.1002/jgh3.12630] [Reference Citation Analysis]
40 Cushing KC, Kordbacheh H, Gee MS, Kambadakone A, Ananthakrishnan AN. Sarcopenia is a Novel Predictor of the Need for Rescue Therapy in Hospitalized Ulcerative Colitis Patients. J Crohns Colitis. 2018;. [PMID: 29762697 DOI: 10.1093/ecco-jcc/jjy064] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
41 Narula N, Marshall JK, Colombel JF, Leontiadis GI, Williams JG, Muqtadir Z, Reinisch W. Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids. Am J Gastroenterol. 2016;111:477-491. [PMID: 26856754 DOI: 10.1038/ajg.2016.7] [Cited by in Crossref: 90] [Cited by in F6Publishing: 77] [Article Influence: 15.0] [Reference Citation Analysis]
42 Grazie ML, Bagnoli S, Dragoni G, Caini S, Annese V, Innocenti T, Deiana S, Manetti N, Milani S, Galli A, Milla M. Infliximab is more effective than cyclosporine as a rescue therapy for acute severe ulcerative colitis: a retrospective single-center study. Ann Gastroenterol 2021;34:370-7. [PMID: 33948062 DOI: 10.20524/aog.2021.0584] [Reference Citation Analysis]
43 Sebastian S, Lisle J, Subramanian S, Dhar A, Shenoy A, Limdi J, Butterworth J, Allen PB, Samuel S, Moran G, Shenderey R, Parkes G, Raine T, Lobo AJ, Kennedy NA. Practice pattern variability in the management of acute severe colitis: a UK provider survey. Frontline Gastroenterol 2020;11:272-9. [PMID: 32587670 DOI: 10.1136/flgastro-2019-101277] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
44 Reinglas J, Gonczi L, Kurt Z, Bessissow T, Lakatos PL. Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases. World J Gastroenterol 2018; 24(32): 3567-3582 [PMID: 30166855 DOI: 10.3748/wjg.v24.i32.3567] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
45 Rivière P, Laharie D, Marteau P. Concise Commentary: Second Line Is Not Second Best-Continuing Validity of the Oxford Criteria in the Management of Acute Severe Ulcerative Colitis. Dig Dis Sci 2020;65:581-2. [PMID: 31489565 DOI: 10.1007/s10620-019-05788-z] [Reference Citation Analysis]
46 Chapman CG, Bochenek A, Stein AC, Rubin DT. Use of Serum Infliximab Level Prior to Cyclosporine Salvage Therapy in Severe Ulcerative Colitis. ACG Case Rep J 2014;1:148-50. [PMID: 26157857 DOI: 10.14309/crj.2014.33] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
47 Fehily SR, Martin FC, Kamm MA. Simple water-based tacrolimus enemas for refractory proctitis. JGH Open 2020;4:561-4. [PMID: 32782938 DOI: 10.1002/jgh3.12280] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
48 Matsuoka K, Saito E, Fujii T, Takenaka K, Kimura M, Nagahori M, Ohtsuka K, Watanabe M. Tacrolimus for the Treatment of Ulcerative Colitis. Intest Res. 2015;13:219-226. [PMID: 26130996 DOI: 10.5217/ir.2015.13.3.219] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
49 Komaki Y, Komaki F, Ido A, Sakuraba A. Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis. J Crohns Colitis. 2016;10:484-494. [PMID: 26645641 DOI: 10.1093/ecco-jcc/jjv221] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 6.1] [Reference Citation Analysis]
50 Chang S, Hudesman D. First-Line Biologics or Small Molecules in Inflammatory Bowel Disease: a Practical Guide for the Clinician. Curr Gastroenterol Rep 2020;22:7. [PMID: 32002688 DOI: 10.1007/s11894-020-0745-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
51 Hutchings HA, Alrubiay L, Watkins A, Cheung WY, Seagrove AC, Williams JG. Validation of the Crohn's and Ulcerative Colitis questionnaire in patients with acute severe ulcerative colitis. United European Gastroenterol J 2017;5:571-8. [PMID: 28588889 DOI: 10.1177/2050640616671627] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
52 Sebastian S, Myers S, Nadir S, Subramanian S. Systematic Review: Efficacy and Safety of Accelerated Induction Regimes in Infliximab Rescue Therapy for Hospitalized Patients with Acute Severe Colitis. Dig Dis Sci. 2019;64:1119-1128. [PMID: 30535888 DOI: 10.1007/s10620-018-5407-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
53 Renna S, Cottone M, Orlando A. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. World J Gastroenterol 2014; 20(29): 9675-9690 [PMID: 25110407 DOI: 10.3748/wjg.v20.i29.9675] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
54 Yamada S, Yoshino T, Matsuura M, Kimura M, Koshikawa Y, Minami N, Toyonaga T, Honzawa Y, Nakase H. Efficacy and Safety of Long-Term Thiopurine Maintenance Treatment in Japanese Patients With Ulcerative Colitis. Intest Res 2015;13:250-8. [PMID: 26131000 DOI: 10.5217/ir.2015.13.3.250] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
55 Eun CS, Han DS. Does the Cyclosporine Still Have a Potential Role in the Treatment of Acute Severe Steroid-Refractory Ulcerative Colitis? Gut Liver 2015;9:567-8. [PMID: 26343066 DOI: 10.5009/gnl15293] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
56 Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015;12:537-545. [PMID: 26284562 DOI: 10.1038/nrgastro.2015.135] [Cited by in Crossref: 164] [Cited by in F6Publishing: 157] [Article Influence: 23.4] [Reference Citation Analysis]
57 Mao TY, Shi R, Zhao WH, Guo Y, Gao KL, Chen C, Xie TH, Li JX. Qingchang Wenzhong Decoction Ameliorates Dextran Sulphate Sodium-Induced Ulcerative Colitis in Rats by Downregulating the IP10/CXCR3 Axis-Mediated Inflammatory Response. Evid Based Complement Alternat Med 2016;2016:4312538. [PMID: 27413386 DOI: 10.1155/2016/4312538] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
58 Shah SC, Naymagon S, Cohen BL, Sands BE, Dubinsky MC. There is Significant Practice Pattern Variability in the Management of the Hospitalized Ulcerative Colitis Patient at a Tertiary Care and IBD Referral Center. J Clin Gastroenterol 2018;52:333-8. [PMID: 28009685 DOI: 10.1097/MCG.0000000000000779] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
59 Wehkamp J, Götz M, Herrlinger K, Steurer W, Stange EF. Inflammatory Bowel Disease. Dtsch Arztebl Int 2016;113:72-82. [PMID: 26900160 DOI: 10.3238/arztebl.2016.0072] [Cited by in Crossref: 20] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
60 Papamichael K, Lin S, Moore M, Papaioannou G, Sattler L, Cheifetz AS. Infliximab in inflammatory bowel disease. Ther Adv Chronic Dis 2019;10:2040622319838443. [PMID: 30937157 DOI: 10.1177/2040622319838443] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 11.0] [Reference Citation Analysis]
61 Singh S, Andersen NN, Andersson M, Loftus EV Jr, Jess T. Comparison of Infliximab and Adalimumab in Biologic-Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study. Clin Gastroenterol Hepatol 2017;15:1218-1225.e7. [PMID: 27913244 DOI: 10.1016/j.cgh.2016.11.024] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
62 Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305-353. [PMID: 29429045 DOI: 10.1007/s00535-018-1439-1] [Cited by in Crossref: 184] [Cited by in F6Publishing: 166] [Article Influence: 46.0] [Reference Citation Analysis]
63 Verdon C, Bessissow T, Lakatos PL. Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules. J Clin Med 2019;8:E2169. [PMID: 31817972 DOI: 10.3390/jcm8122169] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
64 Kucharzik T, Koletzko S, Kannengiesser K, Dignass A. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms.Dtsch Arztebl Int. 2020;117:564-574. [PMID: 33148393 DOI: 10.3238/arztebl.2020.0564] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
65 Szemes K, Soós A, Hegyi P, Farkas N, Erős A, Erőss B, Mezősi E, Szakács Z, Márta K, Sarlós P. Comparable Long-Term Outcomes of Cyclosporine and Infliximab in Patients With Steroid-Refractory Acute Severe Ulcerative Colitis: A Meta-Analysis. Front Med (Lausanne) 2019;6:338. [PMID: 32039218 DOI: 10.3389/fmed.2019.00338] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
66 Mosli MH, Al-Harbi O, Feagan BG, Almadi MA. A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease. Saudi J Gastroenterol. 2015;21:185-197. [PMID: 26228361 DOI: 10.4103/1319-3767.161635] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
67 Kyriakos N, Papaefthymiou A, Giakoumis M, Iatropoulos G, Mantzaris G, Liatsos C. Informed consent in inflammatory bowel disease: a necessity in real-world clinical practice. Ann Gastroenterol 2021;34:466-75. [PMID: 34276184 DOI: 10.20524/aog.2021.0635] [Reference Citation Analysis]
68 Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S; AGA Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology 2020;158:1450-61. [PMID: 31945371 DOI: 10.1053/j.gastro.2020.01.006] [Cited by in Crossref: 67] [Cited by in F6Publishing: 52] [Article Influence: 33.5] [Reference Citation Analysis]
69 Hindryckx P, Jairath V, D'Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol. 2016;13:654-664. [PMID: 27580687 DOI: 10.1038/nrgastro.2016.116] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 9.3] [Reference Citation Analysis]
70 Vitello D, Mcgee MF. Treatment of severe and fulminant colitis. Seminars in Colon and Rectal Surgery 2022. [DOI: 10.1016/j.scrs.2022.100864] [Reference Citation Analysis]
71 Park SC, Jeen YT. Current and emerging biologics for ulcerative colitis. Gut Liver 2015;9:18-27. [PMID: 25547087 DOI: 10.5009/gnl14226] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 8.6] [Reference Citation Analysis]
72 Ho EY, Cominelli F, Katz J. Ulcerative Colitis: What is the Optimal Treatment Goal and How Do We Achieve It? Curr Treat Options Gastroenterol. 2015;13:130-142. [PMID: 25619458 DOI: 10.1007/s11938-014-0044-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
73 Kawai S, Iijima H, Shinzaki S, Hiyama S, Yamaguchi T, Araki M, Iwatani S, Shiraishi E, Mukai A, Inoue T, Hayashi Y, Tsujii M, Motooka D, Nakamura S, Iida T, Takehara T. Indigo Naturalis ameliorates murine dextran sodium sulfate-induced colitis via aryl hydrocarbon receptor activation. J Gastroenterol 2017;52:904-19. [PMID: 27900483 DOI: 10.1007/s00535-016-1292-z] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 6.8] [Reference Citation Analysis]
74 Ganzleben I, Geppert C, Osaba L, Hirschmann S, Nägel A, Glück C, Hoffman A, Rath T, Nagore D, Neurath MF, Atreya R. Successful cyclosporin and ustekinumab combination therapy in a patient with severe steroid-refractory ulcerative colitis. Therap Adv Gastroenterol 2020;13:1756284820954112. [PMID: 33101457 DOI: 10.1177/1756284820954112] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
75 Luo CX, Wen ZH, Zhen Y, Wang ZJ, Mu JX, Zhu M, Ouyang Q, Zhang H. Chinese research into severe ulcerative colitis has increased in quantity and complexity. World J Clin Cases 2018; 6(3): 35-43 [PMID: 29564356 DOI: 10.12998/wjcc.v6.i3.35] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
76 Kayal M, Shah S. Ulcerative Colitis: Current and Emerging Treatment Strategies. J Clin Med 2019;9:E94. [PMID: 31905945 DOI: 10.3390/jcm9010094] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
77 Pellino G, Keller DS, Sampietro GM, Angriman I, Carvello M, Celentano V, Colombo F, Di Candido F, Laureti S, Luglio G, Poggioli G, Rottoli M, Scaringi S, Sciaudone G, Sica G, Sofo L, Leone S, Danese S, Spinelli A, Delaini G, Selvaggi F; Italian Society of Colorectal Surgery SICCR. Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): Crohn's disease. Tech Coloproctol 2020;24:421-48. [PMID: 32172396 DOI: 10.1007/s10151-020-02183-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
78 Holvoet T, Lobaton T, Hindryckx P. Optimal Management of Acute Severe Ulcerative Colitis (ASUC): Challenges and Solutions. Clin Exp Gastroenterol 2021;14:71-81. [PMID: 33727846 DOI: 10.2147/CEG.S197719] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Sobrado CW, Sobrado LF. MANAGEMENT OF ACUTE SEVERE ULCERATIVE COLITIS: A CLINICAL UPDATE. Arq Bras Cir Dig 2016;29:201-5. [PMID: 27759787 DOI: 10.1590/0102-6720201600030017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
80 Jairath V, Chan K, Lasch K, Keeping S, Agboton C, Blake A, Patel H. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis. Expert Rev Gastroenterol Hepatol 2021;15:711-22. [PMID: 33599181 DOI: 10.1080/17474124.2021.1880319] [Reference Citation Analysis]
81 Tanida S, Mizoshita T, Ozeki K, Katano T, Kataoka H, Kamiya T, Joh T. Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2. World J Gastroenterol 2015; 21(29): 8776-8786 [PMID: 26269667 DOI: 10.3748/wjg.v21.i29.8776] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
82 O'Reilly C, O'Sullivan Ó, Cotter PD, O'Connor PM, Shanahan F, Cullen A, Rea MC, Hill C, Coulter I, Ross RP. Encapsulated cyclosporine does not change the composition of the human microbiota when assessed ex vivo and in vivo. J Med Microbiol 2020;69:854-63. [PMID: 31958048 DOI: 10.1099/jmm.0.001130] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
83 Taxonera C, Olivares D, Mendoza JL, Díaz-Rubio M, Rey E. Need for infliximab dose intensification in Crohn’s disease and ulcerative colitis. World J Gastroenterol 2014; 20(27): 9170-9177 [PMID: 25083091 DOI: 10.3748/wjg.v20.i27.9170] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
84 Endo K, Onodera M, Shiga H, Kuroha M, Kimura T, Hiramoto K, Kakuta Y, Kinouchi Y, Shimosegawa T. A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis. Gastroenterol Res Pract. 2016;2016:3162595. [PMID: 26904108 DOI: 10.1155/2016/3162595] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
85 Ban H, Bamba S, Nishida A, Inatomi O, Shioya M, Takahashi KI, Imaeda H, Murata M, Sasaki M, Tsujikawa T, Andoh A. Prognostic factors affecting early colectomy in patients with moderate to severe ulcerative colitis treated with calcineurin inhibitors. Exp Ther Med. 2016;12:829-834. [PMID: 27446283 DOI: 10.3892/etm.2016.3341] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
86 Bürger M, Schmidt C, Teich N, Stallmach A. Medical Therapy of Active Ulcerative Colitis. Viszeralmedizin 2015;31:236-45. [PMID: 26557831 DOI: 10.1159/000436959] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
87 Odes S, Greenberg D. A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases. Clinicoecon Outcomes Res 2014;6:431-43. [PMID: 25336980 DOI: 10.2147/CEOR.S39212] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
88 Seagrove AC, Alam MF, Alrubaiy L, Cheung WY, Clement C, Cohen D, Grey M, Hilton M, Hutchings H, Morgan J. Randomised controlled trial. Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: Trial design and protocol (CONSTRUCT). BMJ Open. 2014;4:e005091. [PMID: 24785401 DOI: 10.1136/bmjopen-2014-005091] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
89 Suzuki T, Mizoshita T, Tanida S, Sugimura N, Katano T, Nishie H, Kataoka H. The efficacy of maintenance therapy after remission induction with tacrolimus in ulcerative colitis with and without previous tumor necrosis factor-α inhibitor. JGH Open 2019;3:217-23. [PMID: 31276039 DOI: 10.1002/jgh3.12140] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
90 Jia X, Guo R, Hu Z, Liu J, Liu J, Li B, Yang Q, He J. Efficacy of infliximab, cyclosporine and tacrolimus on ulcerative colitis: A meta-analysis. Medicine (Baltimore) 2020;99:e22894. [PMID: 33126341 DOI: 10.1097/MD.0000000000022894] [Reference Citation Analysis]
91 Herfarth HH, Rogler G, Higgins PD. Pushing the pedal to the metal: should we accelerate infliximab therapy for patients with severe ulcerative colitis? Clin Gastroenterol Hepatol 2015;13:336-8. [PMID: 25285408 DOI: 10.1016/j.cgh.2014.09.045] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
92 Aggarwal A, Sabol T, Vaziri H. Update on the Use of Biologic Therapy in Ulcerative Colitis. Curr Treat Options Gastroenterol 2017;15:155-67. [PMID: 28120279 DOI: 10.1007/s11938-017-0120-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
93 Xie T, Zhang T, Ding C, Dai X, Li Y, Guo Z, Wei Y, Gong J, Zhu W, Li J. Ulcerative Colitis Endoscopic Index of Severity (UCEIS) vs Mayo Endoscopic Score (MES) in guiding the need for colectomy in patients with acute severe colitis. Gastroenterol Rep (Oxf). 2018;6:38-44. [PMID: 29479441 DOI: 10.1093/gastro/gox016] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 8.2] [Reference Citation Analysis]
94 Bekheit M, Baddour N, Katri K, Taher Y, El Tobgy K, Mousa E. Hyperbaric oxygen therapy stimulates colonic stem cells and induces mucosal healing in patients with refractory ulcerative colitis: a prospective case series. BMJ Open Gastroenterol 2016;3:e000082. [PMID: 27195128 DOI: 10.1136/bmjgast-2016-000082] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
95 Festa S, Scribano ML, Pugliese D, Bezzio C, Principi M, Ribaldone DG, Allocca M, Mocci G, Bodini G, Spagnuolo R, Vernia P, Mazzuoli S, Costa F, Barberio B, Cosintino R, Zerboni G, Aratari A, Armuzzi A, Papi C. Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study. United European Gastroenterol J 2021;9:507-16. [PMID: 33259773 DOI: 10.1177/2050640620977405] [Reference Citation Analysis]
96 Thomas MG, Bayliss C, Bond S, Dowling F, Galea J, Jairath V, Lamb C, Probert C, Timperley-Preece E, Watson A, Whitehead L, Williams JG, Parkes M, Kaser A, Raine T. Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial. BMJ Open 2019;9:e023765. [PMID: 30772849 DOI: 10.1136/bmjopen-2018-023765] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
97 Conley TE, Fiske J, Subramanian S. How to manage: acute severe colitis. Frontline Gastroenterol 2022;13:64-72. [PMID: 34970430 DOI: 10.1136/flgastro-2020-101710] [Reference Citation Analysis]
98 Berinstein JA, Steiner CA, Regal RE, Allen JI, Kinnucan JAR, Stidham RW, Waljee AK, Bishu S, Aldrich LB, Higgins PDR. Efficacy of Induction Therapy With High-Intensity Tofacitinib in 4 Patients With Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019;17:988-990.e1. [PMID: 30458248 DOI: 10.1016/j.cgh.2018.11.022] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 10.0] [Reference Citation Analysis]
99 Gionchetti P, Rizzello F. IBD. Sequential rescue therapy in steroid-refractory ulcerative colitis. Nat Rev Gastroenterol Hepatol 2014;11:521-3. [PMID: 25023033 DOI: 10.1038/nrgastro.2014.126] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
100 Liao X, Zhao Z, Li H, Wu B, Huo J, Li L, Li X, Cao X, Xia M, Wang C, Bai C. Fullerene nanoparticles for the treatment of ulcerative colitis. Sci China Life Sci 2021. [PMID: 34735681 DOI: 10.1007/s11427-021-2001-0] [Reference Citation Analysis]
101 Wong DJ, Roth EM, Feuerstein JD, Poylin VY. Surgery in the age of biologics. Gastroenterol Rep (Oxf). 2019;7:77-90. [PMID: 30976420 DOI: 10.1093/gastro/goz004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
102 Philippou A, Rizvi A, Steinlauf A. Dramatic Deep and Durable Remission of Acute Fulminant Ulcerative Colitis Achieved with Cyclosporine in a Patient Who Failed the Induction Intravenous Phase of Cyclosporine. Case Rep Gastroenterol 2021;15:147-53. [PMID: 33708063 DOI: 10.1159/000512426] [Reference Citation Analysis]
103 Bernstein CN. Treatment of IBD: where we are and where we are going. Am J Gastroenterol. 2015;110:114-126. [PMID: 25488896 DOI: 10.1038/ajg.2014.357] [Cited by in Crossref: 111] [Cited by in F6Publishing: 101] [Article Influence: 13.9] [Reference Citation Analysis]
104 Tarabar D, El Jurdi K, Traboulsi C, Yvellez O, Milenkovic Z, Petrovic S, Subotic B, Gils A, Brocic T, Brcerevic I, Latinovic O, Jocic T, Rubin DT. A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With Vedolizumab. Inflammatory Bowel Diseases 2022. [DOI: 10.1093/ibd/izab328] [Reference Citation Analysis]
105 Osterman MT, Lichtenstein GR. Infliximab vs Adalimumab for UC: Is There A Difference? Clin Gastroenterol Hepatol 2017;15:1197-9. [PMID: 28479503 DOI: 10.1016/j.cgh.2017.04.036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
106 Wu HM, Wei J, Li J, Wang K, Ye L, Qi Y, Yuan BS, Yang YL, Zhao L, Yang Z, Yang MF, Gong JF, Wang FY. Serum Procalcitonin as a Potential Early Predictor of Short-Term Outcomes in Acute Severe Ulcerative Colitis. Dig Dis Sci 2019;64:3263-73. [PMID: 30604378 DOI: 10.1007/s10620-018-5446-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
107 Shen Z, Zheng K, Zou J, Gu P, Xing J, Zhang L, Zhu L, Shen H. Chinese herbal extract granules combined with 5-aminosalicylic acid for patients with moderately active ulcerative colitis: study protocol for a multicenter randomized double-blind placebo-controlled trial. Trials 2021;22:55. [PMID: 33441157 DOI: 10.1186/s13063-020-05012-8] [Reference Citation Analysis]
108 Ordás I, Domènech E, Mañosa M, García-Sánchez V, Iglesias-Flores E, Peñalva M, Cañas-Ventura A, Merino O, Fernández-Bañares F, Gomollón F, Vera M, Gutiérrez A, Garcia-Planella E, Chaparro M, Aguas M, Gento E, Muñoz F, Aguirresarobe M, Muñoz C, Fernández L, Calvet X, Jiménez CE, Montoro MA, Mir A, De Castro ML, García-Sepulcre MF, Bermejo F, Panés J, Esteve M. Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study. Am J Gastroenterol 2017;112:1709-18. [PMID: 28675163 DOI: 10.1038/ajg.2017.180] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 7.8] [Reference Citation Analysis]
109 Ribiere S, Leconte M, Chaussade S, Abitbol V. [Acute severe colitis]. Presse Med 2018;47:312-9. [PMID: 29618409 DOI: 10.1016/j.lpm.2018.02.020] [Reference Citation Analysis]
110 Weisshof R, Ollech JE, El Jurdi K, Yvellez OV, Cohen RD, Sakuraba A, Dalal S, Pekow J, Rubin DT. Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. J Crohns Colitis 2019;13:1105-10. [PMID: 30726894 DOI: 10.1093/ecco-jcc/jjz032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
111 Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489-526. [PMID: 33885977 DOI: 10.1007/s00535-021-01784-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
112 Zhang L, Xue H, Zhao G, Qiao C, Sun X, Pang C, Zhang D. Curcumin and resveratrol suppress dextran sulfate sodium-induced colitis in mice. Mol Med Rep. 2019;19:3053-3060. [PMID: 30816479 DOI: 10.3892/mmr.2019.9974] [Cited by in Crossref: 9] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
113 Minami N, Yoshino T, Matsuura M, Koshikawa Y, Yamada S, Toyonaga T, Madian A, Honzawa Y, Nakase H. Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study. BMJ Open Gastroenterol. 2015;2:e000021. [PMID: 26462273 DOI: 10.1136/bmjgast-2014-000021] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
114 Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389:1756-1770. [PMID: 27914657 DOI: 10.1016/s0140-6736(16)32126-2] [Cited by in Crossref: 830] [Cited by in F6Publishing: 381] [Article Influence: 138.3] [Reference Citation Analysis]
115 Shimizu H, Fujii T, Kinoshita K, Kawamoto A, Hibiya S, Takenaka K, Saito E, Nagahori M, Ohtsuka K, Watanabe M, Okamoto R. Intravenous tacrolimus is a superior induction therapy for acute severe ulcerative colitis compared to oral tacrolimus. BMC Gastroenterol 2021;21:494. [PMID: 34949172 DOI: 10.1186/s12876-021-02043-6] [Reference Citation Analysis]
116 Zhou F, Wu J. Progress in medical treatment of ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2016; 24(20): 3149-3158 [DOI: 10.11569/wcjd.v24.i20.3149] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
117 Singh S, Allegretti JR, Siddique SM, Terdiman JP. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis.Gastroenterology. 2020;158:1465-1496.e17. [PMID: 31945351 DOI: 10.1053/j.gastro.2020.01.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 11.5] [Reference Citation Analysis]
118 Shi YH, Weng Y, Liu ZJ. Detection of serum infliximab concentration for evaluation of treatment efficacy in inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2015; 23(31): 4946-4953 [DOI: 10.11569/wcjd.v23.i31.4946] [Reference Citation Analysis]
119 Rosen MJ, Minar P, Vinks AA. Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2015;41:1094-1103. [PMID: 25809869 DOI: 10.1111/apt.13175] [Cited by in Crossref: 63] [Cited by in F6Publishing: 47] [Article Influence: 9.0] [Reference Citation Analysis]
120 Alexakis C, Pollok RCG. Impact of thiopurines and anti-tumour necrosis factor therapy on hospitalisation and long-term surgical outcomes in ulcerative colitis. World J Gastrointest Surg 2015; 7(12): 360-369 [PMID: 26730281 DOI: 10.4240/wjgs.v7.i12.360] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
121 Nimmons D, Limdi JK. Elderly patients and inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2016; 7(1): 51-65 [PMID: 26855812 DOI: 10.4292/wjgpt.v7.i1.51] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
122 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
123 Hindryckx P, Novak G, Vande Casteele N, Laukens D, Parker C, Shackelton LM, Narula N, Khanna R, Dulai P, Levesque BG, Sandborn WJ, D'Haens G, Feagan BG, Jairath V. Review article: dose optimisation of infliximab for acute severe ulcerative colitis. Aliment Pharmacol Ther. 2017;45:617-630. [PMID: 28074618 DOI: 10.1111/apt.13913] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 8.6] [Reference Citation Analysis]
124 Speight RA, Mansfield JC. Drug advances in inflammatory bowel disease. Clin Med (Lond) 2013;13:378-82. [PMID: 23908509 DOI: 10.7861/clinmedicine.13-4-378] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
125 Kobayashi T, Suzuki Y, Motoya S, Hirai F, Ogata H, Ito H, Sato N, Ozaki K, Watanabe M, Hibi T. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis. J Gastroenterol. 2016;51:241-251. [PMID: 26162647 DOI: 10.1007/s00535-015-1102-z] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 8.3] [Reference Citation Analysis]
126 Paramsothy S, Rosenstein AK, Mehandru S, Colombel JF. The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. Mucosal Immunol 2018;11:1558-70. [PMID: 29907872 DOI: 10.1038/s41385-018-0050-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 9.8] [Reference Citation Analysis]
127 Vaughn BP, Moss AC. Novel treatment options for ulcerative colitis. Clin Investig (Lond) 2013;3:1057-69. [PMID: 24533177 DOI: 10.4155/cli.13.97] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
128 Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia GK, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Ali RAR, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu T, Yang SK, Ouyang Q, Geary R, De Silva JH, Rerknimitr R, Simadibrata M, Abdullah M, Leong RW; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn’s and Colitis. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. Intest Res 2019;17:285-310. [PMID: 31146509 DOI: 10.5217/ir.2019.00026] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 10.0] [Reference Citation Analysis]
129 Lv R, Qiao W, Wu Z, Wang Y, Dai S, Liu Q, Zheng X. Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis. PLoS One. 2014;9:e86692. [PMID: 24475168 DOI: 10.1371/journal.pone.0086692] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
130 Kedia S, Ahuja V, Tandon R. Management of acute severe ulcerative colitis. World J Gastrointest Pathophysiol 2014; 5(4): 579-588 [PMID: 25401001 DOI: 10.4291/wjgp.v5.i4.579] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
131 Zhao HN, Jiang M, Sun MJ, Dai C. The efficacy and safety of infliximab and calcineurin inhibitors in steroid-refractory UC patients: A meta-analysis. Saudi J Gastroenterol 2021;27:191-200. [PMID: 34380865 DOI: 10.4103/sjg.sjg_145_21] [Reference Citation Analysis]
132 Maconi G, Furfaro F, Sciurti R, Bezzio C, Ardizzone S, de Franchis R. Glucose intolerance and diabetes mellitus in ulcerative colitis: Pathogenetic and therapeutic implications. World J Gastroenterol 2014; 20(13): 3507-3515 [PMID: 24707133 DOI: 10.3748/wjg.v20.i13.3507] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
133 Dulai PS, Jairath V. Acute severe ulcerative colitis: latest evidence and therapeutic implications. Ther Adv Chronic Dis. 2018;9:65-72. [PMID: 29387331 DOI: 10.1177/2040622317742095] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
134 Zheng K, Shen H, Jia J, Lu Y, Zhu L, Zhang L, Shen Z. Traditional Chinese medicine combination therapy for patients with steroid-dependent ulcerative colitis: study protocol for a randomized controlled trial. Trials. 2017;18:8. [PMID: 28069051 DOI: 10.1186/s13063-016-1763-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
135 García-Bosch O, Aceituno M, Ordás I, Etchevers J, Sans M, Feu F, Panés J, Ricart E. Long-Term Follow-Up of Patients Treated with Infliximab for Ulcerative Colitis: Predictive Factors of Response-An Observational Study. Dig Dis Sci 2016;61:2051-9. [PMID: 26921082 DOI: 10.1007/s10620-016-4089-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
136 Williams JG, Alam MF, Alrubaiy L, Arnott I, Clement C, Cohen D, Gordon JN, Hawthorne AB, Hilton M, Hutchings HA, Jawhari AU, Longo M, Mansfield J, Morgan JM, Rapport F, Seagrove AC, Sebastian S, Shaw I, Travis SP, Watkins A. Infliximab vs ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomized trial. Lancet Gastroenterol Hepatol. 2016;1:15-24. [PMID: 27595142 DOI: 10.1016/s2468-1253(16)30003-6] [Cited by in Crossref: 108] [Cited by in F6Publishing: 36] [Article Influence: 27.0] [Reference Citation Analysis]
137 Alrubaiy L, Arnott I, Protheroe A, Roughton M, Driscoll R, Williams JG. Inflammatory bowel disease in the UK: is quality of care improving? Frontline Gastroenterol 2013;4:296-301. [PMID: 28839740 DOI: 10.1136/flgastro-2013-100333] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
138 Armuzzi A, Pugliese D, Nardone OM, Guidi L. Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab. Drug Des Devel Ther. 2013;7:289-296. [PMID: 23630414 DOI: 10.2147/dddt.s33197] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
139 Aceituno M, Zabana Y, Esteve M. [Treatment of severe ulcerative colitis flares]. Gastroenterol Hepatol 2014;37:471-9. [PMID: 25015428 DOI: 10.1016/j.gastrohep.2014.05.005] [Reference Citation Analysis]
140 Li X, Xu Y, Zhang C, Deng L, Chang M, Yu Z, Liu D. Protective Effect of Calculus Bovis Sativus on Dextran Sulphate Sodium-Induced Ulcerative Colitis in Mice. Evid Based Complement Alternat Med 2015;2015:469506. [PMID: 26579201 DOI: 10.1155/2015/469506] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
141 Choy MC, Seah D, Faleck DM, Shah SC, Chao CY, An YK, Radford-Smith G, Bessissow T, Dubinsky MC, Ford AC, Churilov L, Yeomans ND, De Cruz PP. Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis. Inflamm Bowel Dis 2019;25:1169-86. [PMID: 30605549 DOI: 10.1093/ibd/izy383] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 13.5] [Reference Citation Analysis]
142 Pellino G, Keller DS, Sampietro GM, Carvello M, Celentano V, Coco C, Colombo F, Geccherle A, Luglio G, Rottoli M, Scarpa M, Sciaudone G, Sica G, Sofo L, Zinicola R, Leone S, Danese S, Spinelli A, Delaini G, Selvaggi F; Italian Society of Colorectal Surgery SICCR. Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): ulcerative colitis. Tech Coloproctol 2020;24:397-419. [PMID: 32124113 DOI: 10.1007/s10151-020-02175-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
143 Saini SD, Waljee AK, Higgins PD. Cost utility of inflammation-targeted therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol 2012;10:1143-51. [PMID: 22610010 DOI: 10.1016/j.cgh.2012.05.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
144 Halpin SJ, Hamlin PJ, Greer DP, Warren L, Ford AC. Efficacy of infliximab in acute severe ulcerative colitis: A single-centre experience. World J Gastroenterol 2013; 19(7): 1091-1097 [PMID: 23467174 DOI: 10.3748/wjg.v19.i7.1091] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
145 Tun GS, Harris A, Lobo AJ. Ulcerative colitis: management in adults, children and young people - concise guidance . Clin Med (Lond) 2017;17:429-33. [PMID: 28974592 DOI: 10.7861/clinmedicine.17-5-429] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
146 Annese V. An update on treatment of ulcerative colitis. Expert Opinion on Orphan Drugs 2019;7:295-304. [DOI: 10.1080/21678707.2019.1638249] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
147 Li X, Xu Y, Zhang C, Deng L, Chang M, Yu Z, Liu D. Protective Effect of Calculus Bovis Sativus on Dextran Sulphate Sodium-Induced Ulcerative Colitis in Mice. Evid Based Complement Alternat Med 2015;2015:469506. [PMID: 26579201 DOI: 10.1155/2015/469506] [Cited by in F6Publishing: 1] [Reference Citation Analysis]